Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 18Nivolumab 7Carboplatin 7durvalumab 5Ipilimumab 5aldesleukin 4Paclitaxel 4Irinotecan 4Gemcitabine 4Docetaxel 4Cisplatin 4sargramostim 3atezolizumab 3Topotecan 3Polymerase Chain Reaction 3Magnetic Resonance Spectroscopy 3temsirolimus 2talazoparib 2carfilzomib 2cabozantinib 2budigalimab 2Trastuzumab 2Therapeutics 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Injections 2Gene Expression Profiling 2Fulvestrant 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × efineptakin alfa × Gynecologic × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡